| Budget Amount *help |
¥17,420,000 (Direct Cost: ¥13,400,000、Indirect Cost: ¥4,020,000)
Fiscal Year 2020: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2019: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2018: ¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
|
|---|
| Outline of Final Research Achievements |
TP53 mutated myelodysplastic syndromes are extremely refractory and there is still no effective treatment. Recently, the demethylating agent, azacitidine, has been reported to have a high remission rate, but many cases eventually relapse. In this study, we showed that TP53 mutated MDS cases have very different biological features and clinical significance depending on allele status (whether one or both of the two human genes are altered), and should be considered as distinct conditions. Furthermore, we examined the size of the mutant cell population (clone) before and after azacitidine treatment, and showed that it is important to examine the type of mutation and its size after treatment in order to understand the pathogenesis and predict prognosis.
|
